Related Experiment Video

Updated: Jun 3, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical

Takashi Kobunai, Toshiaki Watanabe, Yoko Yamamoto

    Pharmacogenomics
    |April 1, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
    12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    Related Experiment Videos

    Last Updated: Jun 3, 2026

    A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
    10:13

    A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

    Published on: July 3, 2013

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
    12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    Related Concept Videos

    Kaplan-Meier Approach01:24

    Kaplan-Meier Approach

    The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity.

    Cell death discovery·2024

    Assessment of the Changes in Mitochondrial Gene Polymorphism in Ulcerative Colitis and the Etiology of Ulcerative Colitis-associated Colorectal Cancer.

    Anticancer research·2020

    CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure.

    Scientific reports·2019

    ChIP-seq Analysis to Explore DNA Replication Profile in Trifluridine-treated Human Colorectal Cancer Cells In Vitro.

    Anticancer research·2019

    Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity.

    Molecular cancer research : MCR·2018

    Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.

    Oncotarget·2018

    Pharmacogenomics of cancer therapy-related cardiomyopathy in childhood cancer survivors.

    Pharmacogenomics·2026

    Pharmacogenomics utilization as a tool for deprescribing in Veterans at high-risk for polypharmacy.

    Pharmacogenomics·2026

    Analysis of the influence of rs1801265 polymorphism on DPD enzyme activity and contributing factors in the Chinese population.

    Pharmacogenomics·2026

    Process evaluation of a pharmacogenomic informed antidepressant prescribing intervention delivered in primary care: findings from the PRESIDE (PhaRmacogEnomicS in Depression) trial.

    Pharmacogenomics·2026

    Associations of SLCO gene polymorphisms with perampanel response and plasma concentrations in patients: a longitudinal retrospective real-world study in refractory epilepsy.

    Pharmacogenomics·2026

    The role of pharmacogenomics in effective pain management with opioids.

    Pharmacogenomics·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us